700 Stock Overview
Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.62 |
| 52 Week High | US$10.68 |
| 52 Week Low | US$9.62 |
| Beta | 1.51 |
| 11 Month Change | -6.47% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -61.21% |
| 5 Year Change | n/a |
| Change since IPO | -57.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 700 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.05% | 0.2% |
| 1Y | n/a | -32.1% | 8.5% |
Return vs Industry: Insufficient data to determine how 700 performed against the German Healthcare Services industry.
Return vs Market: Insufficient data to determine how 700 performed against the German Market.
Price Volatility
| 700 volatility | |
|---|---|
| 700 Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 700's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 700's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,365 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
Certara, Inc. Fundamentals Summary
| 700 fundamental statistics | |
|---|---|
| Market cap | €1.60b |
| Earnings (TTM) | -€29.85m |
| Revenue (TTM) | €358.00m |
4.5x
P/S Ratio-53.7x
P/E RatioIs 700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 700 income statement (TTM) | |
|---|---|
| Revenue | US$372.80m |
| Cost of Revenue | US$150.32m |
| Gross Profit | US$222.48m |
| Other Expenses | US$253.56m |
| Earnings | -US$31.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 59.68% |
| Net Profit Margin | -8.34% |
| Debt/Equity Ratio | 28.1% |
How did 700 perform over the long term?
See historical performance and comparison